Shares of Medpace Holdings Inc. (MEDP) plummeted over 10% in pre-market trading on Tuesday, October 22, as the clinical contract research organization lowered its revenue guidance for the full year 2024.
The company now expects revenue for 2024 to range between $2.09 billion and $2.13 billion, down from its previous guidance of $2.125 billion to $2.175 billion. Despite the lower revenue outlook, Medpace raised its earnings guidance for the year.
The revised guidance, which disappointed investors, led to a sharp sell-off in Medpace's stock during the pre-market session. The company's shares were trading at around $170, down over 10% from the previous close, reflecting the market's reaction to the lowered revenue expectations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。